RAIN US75082Q1058

Rapport

Vertraagde tijd Nasdaq - 22:00 24-06-2022
3.740	USD		+8.72%

23/06	RAIN THERAPEUTICS INC. : JonesTrading Institutional Services nog altijd een koopadvies	MM
02/06	RAIN THERAPEUTICS INC. : Roth Capital Partners herhaalt koopadvies	MM
31/05	RAIN THERAPEUTICS INC. : Piper Sandler herhaalt koopadvies	MM

Nieuws

Aanbevelingen van analisten

Andere talen

Persberichten

Officiële publicaties

Sectornieuws

Communiqués de presse de la société RAIN THERAPEUTICS INC.

03/06	RAIN THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
18/05	Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical On..	AQ
04/05	RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..	AQ
04/05	Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pr..	AQ
20/04	Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Rece..	AQ
01/04	Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the America..	AQ
03/03	RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..	AQ
03/03	RAIN THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Highli..	PU
03/03	RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)	AQ
03/03	Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl..	AQ
24/02	Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Hig..	AQ
08/02	Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments	AQ
31/01	Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference	AQ
25/01	Rain Therapeutics to Present at Upcoming Virtual Investor Conferences	AQ
05/01	Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..	GL
05/01	Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..	GL
2021	Rain Therapeutics to Present at Upcoming Investor Conferences	GL
2021	Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index	AQ
2021	Rain Therapeutics to Present at Upcoming Investor Conferences	AQ
2021	Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-A..	GL
2021	RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..	AQ
2021	Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..	PU
2021	RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)	AQ
2021	Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..	AQ
2021	Research and Development (R&D) Day Presentation - November 2021	PU
2021	Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Mila..	AQ
2021	Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Rece..	AQ
2021	Rain Therapeutics Hosting Research and Development (R&D) Day	GL
2021	RAIN THERAPEUTICS : Hosting Research and Development (R&D) Day	GL
2021	RAIN THERAPEUTICS : Corporate Presentation - October 2021	PU
2021	RAIN THERAPEUTICS : Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virt..	GL
2021	RAIN THERAPEUTICS : to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual Internati..	AQ
2021	Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Confere..	GL
2021	Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conferenc..	GL
2021	Rain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleu..	GL
2021	RAIN THERAPEUTICS : to Present at IASLC 2021 World Conference on Lung Cancer and Participa..	AQ
2021	RAIN THERAPEUTICS : EXECUTIVE SEVERANCE PLAN (Form 8-K)	PU
2021	RAIN THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements a..	AQ
2021	RAIN THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recent Pr..	PU
2021	RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)	AQ
2021	RAIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..	AQ
2021	RAIN THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights Recent Pr..	AQ
2021	Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Rec..	GL
2021	RAIN THERAPEUTICS : Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differen..	AQ
2021	RAIN THERAPEUTICS : Announces Collaboration with Tempus for Genomic Analysis in Planned MD..	AQ
2021	RAIN THERAPEUTICS : Announces Patient Referral Partnership for the Planned MDM2-Amplified ..	AQ
2021	RAIN THERAPEUTICS : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conferen..	AQ
2021	RAIN THERAPEUTICS : Reports First Quarter 2021 Financial Results and Highlights Recent Pro..	PU
2021	RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)	AQ
2021	RAIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..	AQ
2021	RAIN THERAPEUTICS : Reports First Quarter 2021 Financial Results and Highlights Recent Pro..	AQ
2021	RAIN THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)	AQ
2021	RAIN THERAPEUTICS : Appoints Robert Doebele, M.D., Ph.D. as President	AQ
2021	RAIN THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..	AQ

Volgende evenement op RAIN THERAPEUTICS INC.

09/08/22

Eerste halfjaar 2022 Cijferpublicaties (schatting)

De agenda van het bedrijf

Komende gebeurtenissen in de sector

27/07/22	VERTEX PHARMACEUTICALS INCORPORATED : Eerste halfjaar 2022 Cijferpublicaties (schatting)
27/07/22	GILEAD SCIENCES, INC. : Eerste halfjaar 2022 Cijferpublicaties (schatting)
04/08/22	REGENERON PHARMACEUTICALS, INC. : Eerste halfjaar 2022 Cijferpublicaties (schatting)
08/08/22	BIONTECH SE : Eerste halfjaar 2022 Cijferpublicaties

Meer evenementen

Sector

Gezondheidszorg
	Farmaceutisch en medisch onderzoek
		Biotechnologie & Medisch Onderzoek
			Biotechnologie & Medisch Onderzoek
				Biotherapeutische geneesmiddelen